PET imaging of the neurovascular interface in cerebrovascular disease

Evans, Nicholas; Tarkin, Jason M.; Buscombe, J. R.; Markus, Hugh S.; Rudd, James H.F.; Warburton, Elizabeth A.

doi:10.1038/nrneurol.2017.129

Cited by 40 publications

(25 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 Variable resolution acquisitions in healthy human subjects showed cardiac structure and neuro-vasculature in the pyruvate data set that would otherwise be missed due to partial-volume effects and illustrates the level of detail that can be achieved with hyperpolarized substrates in a clinical setting, approaching that of 1 H MRSI and some positron emission tomography (PET) radiotracers. [42][43][44][45] A variable resolution approach would also be beneficial when the biodistribution of metabolites is the primary interest 34 or when performing co-polarization studies with inert perfusion agents, such as 13 C urea, 46 and would provide an opportunity to acquire F I G U R E 6 AUC images from a healthy cardiac volunteer. The pyruvate data, acquired at finer resolution, provides improved contrast between the left and right ventricles and the myocardium and papillary muscles.…”

Section: Discussionmentioning

confidence: 99%

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI

Gordon

Autry

Tang

et al. 2020

Magnetic Resonance in Med

View full text Add to dashboard Cite

Purpose To ameliorate tradeoffs between a fixed spatial resolution and signal‐to‐noise ratio (SNR) for hyperpolarized 13C MRI. Methods In MRI, SNR is proportional to voxel volume but retrospective downsampling or voxel averaging only improves SNR by the square root of voxel size. This can be exploited with a metabolite‐selective imaging approach that independently encodes each compound, yielding high‐resolution images for the injected substrate and coarser resolution images for downstream metabolites, while maintaining adequate SNR for each. To assess the efficacy of this approach, hyperpolarized [1‐13C]pyruvate data were acquired in healthy Sprague‐Dawley rats (n = 4) and in two healthy human subjects. Results Compared with a constant resolution acquisition, variable‐resolution data sets showed improved detectability of metabolites in pre‐clinical renal studies with a 3.5‐fold, 8.7‐fold, and 6.0‐fold increase in SNR for lactate, alanine, and bicarbonate data, respectively. Variable‐resolution data sets from healthy human subjects showed cardiac structure and neuro‐vasculature in the higher resolution pyruvate images (6.0 × 6.0 mm2 for cardiac and 7.5 × 7.5 mm2 for brain) that would otherwise be missed due to partial‐volume effects and illustrates the level of detail that can be achieved with hyperpolarized substrates in a clinical setting. Conclusion We developed a variable‐resolution strategy for hyperpolarized 13C MRI using metabolite‐selective imaging and demonstrated that it mitigates tradeoffs between a fixed spatial resolution and SNR for hyperpolarized substrates, providing both high resolution pyruvate and coarse resolution metabolite data sets in a single exam. This technique shows promise to improve future studies by maximizing metabolite SNR while minimizing partial‐volume effects from the injected substrate.

show abstract

Section: Discussionmentioning

confidence: 99%

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI

Gordon

Autry

Tang

et al. 2020

Magnetic Resonance in Med

View full text Add to dashboard Cite

show abstract

“…PET scans operate on the principle that positron-emitting radioligands accumulate in a region of interest. The positively-charged positrons encounter negatively-charged electrons, which results in annihilation releasing gamma photons that are detected by scintillation detectors [ 16 ]. This method can be used to image Aβ in vivo via radiolabeled tracers, which are injected via a bolus injection, followed by a waiting period to allow for uptake by brain tissue.…”

Section: Imaging Amyloid Burdenmentioning

confidence: 99%

Neuroimaging Biomarkers for Alzheimer’s Disease

Márquez¹,

Yassa²

2019

Mol Neurodegeneration

189

118

View full text Add to dashboard Cite

Currently, over five million Americans suffer with Alzheimer’s disease (AD). In the absence of a cure, this number could increase to 13.8 million by 2050. A critical goal of biomedical research is to establish indicators of AD during the preclinical stage (i.e. biomarkers) allowing for early diagnosis and intervention. Numerous advances have been made in developing biomarkers for AD using neuroimaging approaches. These approaches offer tremendous versatility in terms of targeting distinct age-related and pathophysiological mechanisms such as structural decline (e.g. volumetry, cortical thinning), functional decline (e.g. fMRI activity, network correlations), connectivity decline (e.g. diffusion anisotropy), and pathological aggregates (e.g. amyloid and tau PET). In this review, we survey the state of the literature on neuroimaging approaches to developing novel biomarkers for the amnestic form of AD, with an emphasis on combining approaches into multimodal biomarkers. We also discuss emerging methods including imaging epigenetics, neuroinflammation, and synaptic integrity using PET tracers. Finally, we review the complementary information that neuroimaging biomarkers provide, which highlights the potential utility of composite biomarkers as suitable outcome measures for proof-of-concept clinical trials with experimental therapeutics.

show abstract

“…[7][8][9][10] In 2017, Li et al 11 demonstrated that CoCl 2 -induced hypoxia promoted cell migration and proliferation in placenta-derived mesenchymal stem cells. [7][8][9][10] In 2017, Li et al 11 demonstrated that CoCl 2 -induced hypoxia promoted cell migration and proliferation in placenta-derived mesenchymal stem cells.…”

mentioning

confidence: 99%

MALAT1 promoted cell proliferation and migration via MALAT1/miR‐155/MEF2A pathway in hypoxia of cardiac stem cells

Wang

Chen

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Accumulating evidence revealed that hypoxia contributed to many human diseases, including ischemic myocardium and heart failure (HF). In recent years, the roles of hypoxia in stem cell survival and cardiac biology have been studied extensively. However, the underlying molecular mechanisms remain to be elucidated. As a leading cause of HF, ischemic heart disease was correlated with hypoxia. In this study, we firstly constructed the hypoxia cell model by CoCl2 in cardiac stem cells (CSCs) and found that hypoxia induced the cell proliferation and migration potential in CSCs. Then, we demonstrated that the expression of metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) was promoted in CoCl2‐induced CSCs hypoxia model. Furthermore, we found that knockdown of MALAT1 inhibited the cell proliferation and migration in CoCl2‐induced CSCs hypoxia model. In addition, we revealed that MALAT1 regulated the microRNA‐155 (miR‐155) expression in CSCs under both the normal and hypoxia conditions and further, manipulation of the miR‐155 expression affected the role of MALAT1 in CoCl2‐induced CSCs hypoxia cell model. We then illustrated that miR‐155 regulated the myocyte enhancer factor 2A (MEF2A) expression in CSCs under both the normal and hypoxia conditions and further, changing the expression of MEF2A affected the role of miR‐155. Finally, we demonstrated that MALAT1 regulated the MEF2A expression and exerted its role via modulation of the MALAT1/miR‐155/MEF2A pathway. Taken together, our study illustrated that MALAT1 promoted the cell proliferation and migration in CoCl2‐induced CSCs hypoxia model, acting mechanistically by promoting MEF2A expression via “sponging” miR‐155.

show abstract

PET imaging of the neurovascular interface in cerebrovascular disease

Cited by 40 publications

References 149 publications

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI

Neuroimaging Biomarkers for Alzheimer’s Disease

MALAT1 promoted cell proliferation and migration via MALAT1/miR‐155/MEF2A pathway in hypoxia of cardiac stem cells

Contact Info

Product

Resources

About

PET imaging of the neurovascular interface in cerebrovascular disease

Cited by 40 publications

References 149 publications

A variable resolution approach for improved acquisition of hyperpolarized 13C metabolic MRI

A variable resolution approach for improved acquisition of hyperpolarized 13C metabolic MRI

Neuroimaging Biomarkers for Alzheimer’s Disease

MALAT1 promoted cell proliferation and migration via MALAT1/miR‐155/MEF2A pathway in hypoxia of cardiac stem cells

Contact Info

Product

Resources

About

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI

A variable resolution approach for improved acquisition of hyperpolarized ¹³C metabolic MRI